Living in LALA land? Forty years of attenuating Fc effector functions
2024
Forty Years of Attenuating Fc Effector Functions
publication
10 minutes
Evidence: moderate
Author Information
Author(s): Geoff Hale
Primary Institution: mAbsolve Limited
Hypothesis
Can the development of antibody variants improve safety and efficacy in therapeutic applications?
Conclusion
The study reviews the evolution of antibody variants aimed at silencing unwanted Fc receptor interactions, highlighting both successes and ongoing challenges.
Supporting Evidence
- Over 45 different antibody variants have entered clinical trials to reduce unwanted Fc receptor interactions.
- The LALA variant is the most widely used for silencing Fc effector functions.
- Fc silencing can improve the safety profile of therapeutic antibodies, but some variants still show residual activity.
Takeaway
Scientists have been working for 40 years to make antibodies safer by changing parts of them that can cause bad reactions in patients.
Methodology
The review analyzes various antibody variants developed over the years to reduce unwanted Fc receptor binding.
Limitations
The review does not provide new experimental data but summarizes existing knowledge and clinical experiences.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website